Physician profile
Cong T Phan
NPI 1386778033
$1,969.61
in general payments reported to CMS, 2019-2025
30 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $46.30 · 2021: $149 · 2022: $305 · 2023: $85.09 · 2024: $441 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $475.21 | 2019-2024 | Xarelto |
| Pfizer INC. | $184.65 | 2022-2025 | |
| Abbvie INC. | $145.56 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $137.97 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.95 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $90.35 | 2024-2025 | Jardiance |
| Shield Therapeutics INC | $72.73 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.92 | 2024-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $59.91 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.47 | 2022 | |
| Novo Nordisk INC | $55.91 | 2021-2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $43.04 | 2021-2022 | |
| Exact Sciences Corporation | $42.21 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $41.45 | 2024-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $38.29 | 2020-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.30 | 2025 | Otezla, Repatha |
| Ardelyx, INC. | $33.26 | 2025 | Ibsrela |
| Scilex Pharmaceuticals INC. | $32.41 | 2019 | |
| Allergan, INC. | $28.73 | 2019 | |
| Alk-Abello, INC | $25.04 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $24.73 | 2025 | Breztri |
| Eisai INC. | $24.48 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.07 | 2024 | Gvoke Hypopen |
| Phadia US INC. | $22.25 | 2024 | Immunocap |
| Companion Medical, INC. | $20.56 | 2019 | |
| La Jolla Pharmaceutical Company | $19.22 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2022 | |
| Globus Medical, INC. | $15.38 | 2025 | Senza |
| Philips North America LLC | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cong Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.